2016 ASCO Annual Meeting Abstract LBA4: Phase III Randomized Controlled Study of Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR Study

D significantly improved PFS, TTP, and ORR in combination with Vd vs Vd alone. DVd doubled both VGPR and sCR/CR rates vs Vd alone. Safety of DVd is consistent with the known safety profile of D and Vd. The addition of D to Vd should be considered a new standard of care for RRMM pts currently receiving Vd alone.